Immatics Presents Data Update on Dose Escalation from Ongoing ACTengine® Cell Therapy Programs
·
cancer
·
Tumor shrinkage observed in 8 out of 10 patients including one partial response consistent with robust biological activity of infused T cell products
·
Houston, Texas and Tuebingen, Germany, March 17, 2021 –
Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced a clinical data update from the dose escalation cohorts of the company’s ongoing Phase 1 trials for its engineered Adoptive Cell Therapy approach (also known as TCR-T). The treatment of patients with ACTengine® product candidates IMA201, IMA202 and IMA203 at initial dose levels below one billion transduced cells, intended to establish safety and first biological activity, showed first anti-tumor activity with 9 out of 10 evaluable patients showing disease control as
Immatics Presents Data Update on Dose Escalation from Ongoing ACTengine® Cell Therapy Programs apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
Published: Mar 11, 2021
New Drug Application (“NDA”) submitted to the U.S. Food and Drug Administration (“FDA”) for BXCL501 for the acute treatment of schizophrenia and bipolar disorder related agitation
TRANQUILITY achieved primary and secondary endpoints with both doses of BXCL501; End of Phase 2 meeting with the FDA planned for Q2 2021
RELEASE trial on track to report topline results in Q1 2021
Topline results from two ongoing trials with BXCL701 in aggressive forms of prostate cancer and advanced solid tumors are expected in mid-2021
Company to host conference call today at 8:30 a.m. ET
NEW HAVEN, Conn., March 11, 2021 (GLOBE NEWSWIRE) BioXcel, Inc. (“BioXcel” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced its quarterly results for the fourth quarter and full year ended December 31, 2020
In Pittsfield, lower taxes favored over school staffing
Poll workers Elizabeth Hast and Roberta Maxfield assisting voter Jason Isabelle at Pittsfield Middle High School in Pittsfield on Tuesday, March 9, 2021. Melissa Curran Monitor staff
Voter Daniel Mullen receives his ballot from poll worker Cara Marston and Leslie Voght at Pittsfield Middle High School in Pittsfield on Tuesday. Melissa Curran / Monitor staff
Seventh and eighth graders listen to English teacher Chris Davitt (center) during an interdisciplinary humanities block at Pittsfield Middle High School on Wednesday, Dec. 21, 2016. (ELIZABETH FRANTZ / Monitor staff) Elizabeth Frantz
Published: 3/10/2021 4:10:25 PM
Voters in Pittsfield, asked to choose between cuts to school staff and lower property taxes, or stability in their educational programs and higher taxes, spoke with pinched wallets on Election Day.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
BioXcel Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides .
BioXcel TherapeuticsMarch 11, 2021 GMT
New Drug Application (“NDA”) submitted to the U.S. Food and Drug Administration (“FDA”) for BXCL501 for the acute treatment of schizophrenia and bipolar disorder related agitation
TRANQUILITY achieved primary and secondary endpoints with both doses of BXCL501; End of Phase 2 meeting with the FDA planned for Q2 2021
RELEASE trial on track to report topline results in Q1 2021
Topline results from two ongoing trials with BXCL701 in aggressive forms of prostate cancer and advanced solid tumors are expected in mid-2021